|LETTER TO EDITOR
|Year : 2018 | Volume
| Issue : 5 | Page : 196-197
Levels of tumor markers in human immunodeficiency virus patients: Results of a pilot study
Saif Ullah Munshi, Afsana Anwar Miti, Md Nazmul Karim, Shahina Tabssum
Department of Virology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
|Date of Web Publication||10-Jan-2019|
Prof. Saif Ullah Munshi
Department of Virology, Bangabandhu Sheikh Mujib Medical University, Dhaka
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Munshi SU, Miti AA, Karim MN, Tabssum S. Levels of tumor markers in human immunodeficiency virus patients: Results of a pilot study. Clin Cancer Investig J 2018;7:196-7
|How to cite this URL:|
Munshi SU, Miti AA, Karim MN, Tabssum S. Levels of tumor markers in human immunodeficiency virus patients: Results of a pilot study. Clin Cancer Investig J [serial online] 2018 [cited 2019 Jan 17];7:196-7. Available from: http://www.ccij-online.org/text.asp?2018/7/5/196/249810
Human immunodeficiency virus (HIV)-infected patients are at higher risk of development of cancers including Kaposi sarcoma, Hodgkin's and non-Hodgkin lymphoma, and cancers in different organs., Though antiretroviral therapy (ART) increases life expectancy, it in turn increases the number of patients and increased risk of malignancy. Hence, cancer screening is essential for HIV patients.
For cancer screening and observing prognosis after treatment, several nonspecific tumor markers of blood such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9), and prostate-specific antigen (PSA) are used. However, data regarding screening HIV patients before and after ART are inadequate. Therefore, this pilot study (IRB/BSMMU/2010/12167-A) was conducted among HIV patients, which have two study components, i.e., cross sectional and prospective [Table 1]. In the cross-sectional part, three groups of study participants were assayed for the levels of the above-mentioned tumor markers in blood. The groups were as follows: Group I: HIV patients with CD4 T-cell count (cells/μl) >350 (n = 16; male: female = 8:8), Group II: HIV patients with CD4 T-cell count <350 (n = 24; male: female = 12:9), and Group III: HIV patients on ART for 2 years (n = 19; male: female = 12:7). In the prospective part, the Group II was screened again after 3 months of ART (n = 21; male: female = 12:9). The tumor markers, CD4/CD8 T-cells, and viral loads were measured by chemiluminescence immunoassay (IMMULITE®, Germany), flowcytometry (FACSCount, BD Biosciences, USA), and real-time polymerase chain reaction (Applied Biosystems, USA), respectively.
|Table 1: Levels of tumor markers among human immunodeficiency virus patients categorized according to their CD4 T cell count and anti-retroviral therapy status|
Click here to view
Among the tumor markers, the median value of CEA was higher in Group II (median interquartile range [IQR]; 2.0 [1.4, 3.9]) compared to Group I (median [IQR]; 1.1 [0.9, 1.4]) and Group III (median [IQR]; 1.1 [0.9, 2.0]). This shows that the advanced stage of HIV disease may be linked to higher levels of CEA, and long-term use of ART improves the condition and reduces CEA level. No significant difference, however, was observed in PSA and CA 19.9 levels across the groups. Though paired comparison between before and after 3-month ART revealed no significant difference in any of the tumor markers, 5 (20.8%) and 6 (25%) HIV patients of Group II had abnormal level of CA 19-9 and CEA before initiation of ART, and in the prospective part of the study, only 4.8% patients had abnormal level of CA 19-9 and CEA after 3 months of ART. During the study period, two patients with elevated CA 19-9 and CEA died and one lost in follow-up. Though the change in CEA level was not apparent 3 months after ART, the level found comparable to the level of Group I after 2 years of ART, suggesting a potential role of prolonged use of ART in reducing CEA level. An elevated level of CEA in AIDS patients with Pneumocystis carinii pneumonia was reported previously. Although the elevated levels of CA 19-9 and PSA were reported in AIDS patients, the present study contradicts those findings.,
Though lack of power was one limitation of this pilot study, findings of this study indicate a requirement of future study on a large population of HIV patients to see if there is any change in tumor markers in disease and therapy.
We wish to acknowledge the financial support from the Director General of Health, Bangladesh.
Financial support and sponsorship
The study was supported by Grants from Directorate General of Health Services, Bangladesh.
Conflicts of interest
There are no conflicts of interest.
| References|| |
Gotti D, Raffetti E, Albini L, Sighinolfi L, Maggiolo F, Di Filippo E, et al.
Survival in HIV-infected patients after a cancer diagnosis in the cART era: Results of an Italian multicenter study. PLoS One 2014;9:e94768.
Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009;52:611-22.
Bédos JP, Hignette C, Lucet JC, Kilani B, Casalino E, Wolff M, et al.
Serum carcinoembryonic antigen: A prognostic marker in HIV-related pneumocystis carinii pneumonia. Scand J Infect Dis 1992;24:309-15.
Hocqueloux L, Gervais A. Cholangiocarcinoma and AIDS-related sclerosing cholangitis. Ann Intern Med 2000;132:1006-7.
Vianna LE, Lo Y, Klein RS. Serum prostate-specific antigen levels in older men with or at risk of HIV infection. HIV Med 2006;7:471-6.